Sign in
Taking people in South KoreaNo phase

FURESTEM-OA-Kit injection for knee osteoarthritis in people who earlier received placebo

Tests FURESTEM-OA-Kit in adults with knee osteoarthritis who previously received placebo.

Key facts

Who runs it
Kang Stem Biotech Co., Ltd.
Where
Seoul, South KoreaSee the 2 sites
Trial code
Registry title
A Multicenter, Open-Label, Single-Arm Extension Study to Evaluate the Safety and Efficacy of FURESTEM-OA-Kit Inj. in Knee Osteoarthritis Patients Who Received Placebo in the K0701 Phase 2a Trial
Status
Recruiting
People taking part
36 people, planned
Started
20 Jul 2026
Expected to end
28 Feb 2032
Type of study
Observational
Record updated
10 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with knee osteoarthritis who got placebo (a dummy treatment) in the K0701 trial. They must also have finished its long-term follow-up study.

Age
19 Years and older
Sex
All sexes
Disease stage
Knee osteoarthritis
Earlier treatment
Must have received placebo in the K0701 clinical trial and completed the long-term follow-up study.

Main reasons for not taking part

  • The study doctor judges the person should not take part in this extension study
  • Pregnant or breastfeeding women
  • Women who could become pregnant, or men, who do not agree to use birth control during the study

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Participants who received placebo in the K0701 clinical trial and completed the Long-term follow-up study
  • Participants who voluntarily provide written informed consent to participate in this extension study

Who cannot take part

  • Participants meeting any of the following criteria:
  • Participants whom the investigator considers unsuitable for participation in this extension study
  • Pregnant or breastfeeding women, and women of childbearing potential or men who do not agree to use an appropriate method of contraception during the study

Where in South Korea

  • CHA University Bundang Medical CenterSeoul, South KoreaContact: Jae Young Park, professorTaking people
  • Kyung Hee University HospitalSeoul, South KoreaContact: Kyoung Ho Yoon Yoon, professor (principal investigator)Not yet recruiting

About the trial

What the trial wants to find out

A Multicenter, Open-Label, Single-Arm Extension Study to Evaluate the Safety and Efficacy of FURESTEM-OA-Kit Inj. in Knee Osteoarthritis Patients Who Received Placebo in the K0701 Phase 2a Trial

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Open-Label, Single-Arm Extension Study to Evaluate the Safety and Efficacy of FURESTEM-OA-Kit Inj. in Knee Osteoarthritis Patients Who Received Placebo in the K0701 Phase 2a Trial
Plain-language title
FURESTEM-OA-Kit injection for knee osteoarthritis in people who earlier received placeboGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
10 August 2026